Phathom Pharmaceuticals, Inc. Revenue per Share

Revenue per Share of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Revenue per Share growth rates and interactive chart. Calculated as total revenue divided by the number of weighted average shares outstanding in the period. It can be easily compared to the stock price to determine how revenue is an investor getting for every $1 paid for a stock.


Highlights and Quick Summary

  • Revenue per Share for the quarter ending September 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Revenue per Share decreased by NaN%
  • Annual Revenue per Share for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual Revenue per Share for 2019 was 0.0 (a NaN% decrease from previous year)
  • Twelve month Revenue per Share ending September 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Revenue per Share decreased by NaN% year-over-year
Trailing Revenue per Share for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
0.0 0.0 0.0 0.0
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Revenue per Share of Phathom Pharmaceuticals, Inc.

Most recent Revenue per Shareof PHAT including historical data for past 10 years.

Interactive Chart of Revenue per Share of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Revenue per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0 0.0 0.0
2020 0.0 0.0 0.0 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.